EVO
Price
$3.48
Change
-$0.06 (-1.69%)
Updated
Sep 26 closing price
Capitalization
1.26B
39 days until earnings call
OGI
Price
$1.69
Change
-$0.06 (-3.43%)
Updated
Sep 26 closing price
Capitalization
227.59M
Interact to see
Advertisement

EVO vs OGI

Header iconEVO vs OGI Comparison
Open Charts EVO vs OGIBanner chart's image
Evotec SE
Price$3.48
Change-$0.06 (-1.69%)
Volume$14.1K
Capitalization1.26B
Organigram Global
Price$1.69
Change-$0.06 (-3.43%)
Volume$471.31K
Capitalization227.59M
EVO vs OGI Comparison Chart in %
Loading...
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EVO vs. OGI commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVO is a StrongBuy and OGI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (EVO: $3.48 vs. OGI: $1.69)
Brand notoriety: EVO and OGI are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EVO: 27% vs. OGI: 59%
Market capitalization -- EVO: $1.26B vs. OGI: $227.59M
EVO [@Pharmaceuticals: Generic] is valued at $1.26B. OGI’s [@Pharmaceuticals: Generic] market capitalization is $227.59M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.83B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVO’s FA Score shows that 1 FA rating(s) are green whileOGI’s FA Score has 1 green FA rating(s).

  • EVO’s FA Score: 1 green, 4 red.
  • OGI’s FA Score: 1 green, 4 red.
According to our system of comparison, OGI is a better buy in the long-term than EVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVO’s TA Score shows that 4 TA indicator(s) are bullish while OGI’s TA Score has 3 bullish TA indicator(s).

  • EVO’s TA Score: 4 bullish, 4 bearish.
  • OGI’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, EVO is a better buy in the short-term than OGI.

Price Growth

EVO (@Pharmaceuticals: Generic) experienced а -4.40% price change this week, while OGI (@Pharmaceuticals: Generic) price change was -6.11% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.16%. For the same industry, the average monthly price growth was +24.25%, and the average quarterly price growth was +66.99%.

Reported Earning Dates

EVO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.16% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EVO($1.26B) has a higher market cap than OGI($228M). OGI YTD gains are higher at: 4.969 vs. EVO (-16.346). OGI has higher annual earnings (EBITDA): -959K vs. EVO (-121.33M). EVO has more cash in the bank: 356M vs. OGI (36.8M). OGI has less debt than EVO: OGI (9.15M) vs EVO (107M). EVO has higher revenues than OGI: EVO (777M) vs OGI (224M).
EVOOGIEVO / OGI
Capitalization1.26B228M552%
EBITDA-121.33M-959K12,651%
Gain YTD-16.3464.969-329%
P/E RatioN/A195.72-
Revenue777M224M347%
Total Cash356M36.8M967%
Total Debt107M9.15M1,170%
FUNDAMENTALS RATINGS
EVO vs OGI: Fundamental Ratings
EVO
OGI
OUTLOOK RATING
1..100
7717
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9589
PRICE GROWTH RATING
1..100
5941
P/E GROWTH RATING
1..100
21
SEASONALITY SCORE
1..100
8575

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OGI's Valuation (87) in the null industry is in the same range as EVO (93). This means that OGI’s stock grew similarly to EVO’s over the last 12 months.

OGI's Profit vs Risk Rating (100) in the null industry is in the same range as EVO (100). This means that OGI’s stock grew similarly to EVO’s over the last 12 months.

OGI's SMR Rating (89) in the null industry is in the same range as EVO (95). This means that OGI’s stock grew similarly to EVO’s over the last 12 months.

OGI's Price Growth Rating (41) in the null industry is in the same range as EVO (59). This means that OGI’s stock grew similarly to EVO’s over the last 12 months.

OGI's P/E Growth Rating (1) in the null industry is in the same range as EVO (2). This means that OGI’s stock grew similarly to EVO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EVOOGI
RSI
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
77%
Momentum
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bullish Trend 3 days ago
62%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
74%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 13 days ago
69%
Bullish Trend 5 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
77%
Bullish Trend 3 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PCSMX16.170.18
+1.13%
Principal SmallCap Growth I R6
NSCRX53.690.51
+0.96%
Nuveen Small-Cap Value Opps I
WEEIX11.450.09
+0.79%
TETON Westwood Equity I
PSPJX31.740.19
+0.60%
Principal Large Cap S&P 500 Index J
ALBAX89.000.34
+0.38%
Alger Growth & Income A

EVO and

Correlation & Price change

A.I.dvisor tells us that EVO and ACB have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EVO and ACB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVO
1D Price
Change %
EVO100%
-1.69%
ACB - EVO
29%
Poorly correlated
-1.82%
OGI - EVO
27%
Poorly correlated
-3.43%
CGC - EVO
24%
Poorly correlated
-2.19%
TAK - EVO
23%
Poorly correlated
+0.61%
ELAN - EVO
22%
Poorly correlated
+3.65%
More

OGI and

Correlation & Price change

A.I.dvisor indicates that over the last year, OGI has been loosely correlated with ACB. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if OGI jumps, then ACB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OGI
1D Price
Change %
OGI100%
-3.43%
ACB - OGI
63%
Loosely correlated
-1.82%
CGC - OGI
61%
Loosely correlated
-2.19%
TLRY - OGI
60%
Loosely correlated
-3.36%
CRON - OGI
59%
Loosely correlated
-0.38%
HROW - OGI
35%
Loosely correlated
+2.06%
More